Biomarin Pharmaceutical Inc (BMRN)
92.78
+0.74
(+0.80%)
USD |
NASDAQ |
Apr 24, 10:13
Biomarin Pharmaceutical Accounts Payable (Quarterly): 315.51M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 315.51M |
September 30, 2023 | 301.37M |
June 30, 2023 | 277.94M |
March 31, 2023 | 264.78M |
December 31, 2022 | 231.24M |
September 30, 2022 | 207.16M |
June 30, 2022 | 199.25M |
March 31, 2022 | 187.81M |
December 31, 2021 | 199.68M |
September 30, 2021 | 203.32M |
June 30, 2021 | 176.07M |
March 31, 2021 | 165.00M |
December 31, 2020 | 191.43M |
September 30, 2020 | 218.02M |
June 30, 2020 | 205.87M |
March 31, 2020 | 235.16M |
December 31, 2019 | 240.98M |
September 30, 2019 | 226.77M |
June 30, 2019 | 223.95M |
March 31, 2019 | 224.38M |
December 31, 2018 | 207.62M |
September 30, 2018 | 177.40M |
June 30, 2018 | 166.42M |
March 31, 2018 | 172.19M |
December 31, 2017 | 166.62M |
Date | Value |
---|---|
September 30, 2017 | 157.02M |
June 30, 2017 | 158.23M |
March 31, 2017 | 135.60M |
December 31, 2016 | 191.35M |
September 30, 2016 | 148.77M |
June 30, 2016 | 153.65M |
March 31, 2016 | 152.86M |
December 31, 2015 | 179.29M |
September 30, 2015 | 162.93M |
June 30, 2015 | 135.77M |
March 31, 2015 | 130.07M |
December 31, 2014 | 139.51M |
September 30, 2014 | 115.75M |
June 30, 2014 | 101.05M |
March 31, 2014 | 79.72M |
December 31, 2013 | 95.30M |
September 30, 2013 | 74.30M |
June 30, 2013 | 68.36M |
March 31, 2013 | 69.81M |
December 31, 2012 | 67.15M |
September 30, 2012 | 11.46M |
June 30, 2012 | 12.50M |
March 31, 2012 | 12.44M |
December 31, 2011 | 36.09M |
September 30, 2011 | 7.107M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
165.00M
Minimum
Mar 2021
315.51M
Maximum
Dec 2023
224.81M
Average
218.02M
Median
Sep 2020
Accounts Payable (Quarterly) Benchmarks
Eli Lilly and Co | 2.599B |
Merck & Co Inc | 3.922B |
Pfizer Inc | 6.71B |
Bristol-Myers Squibb Co | 3.259B |
Moderna Inc | 520.00M |